David H. Forand

We don’t have enough information about this author to calculate their statistics. If you think this is an error let us know.
Learn More
PURPOSE To define the maximum-tolerated dose, recommended phase II dose (RD), dose-limiting toxicity (DLT), and pharmacokinetics of a novel taxane, RPR 109881A, administered on days 1 and 8 of a(More)
  • 1